Protein Summary
Splice factor that binds to the single-stranded 3'AG at the exon/intron border and promotes its utilization in the second catalytic step. Involved in the regulation of alternative splicing and the utilization of cryptic splice sites. Promotes the utilization of a cryptic splice site created by the beta-110 mutation in the HBB gene. The resulting frameshift leads to sickle cell anemia. This gene encodes an RNA binding protein. The encoded protein is part of the spliceosome complex and functions in the second catalytic step of mRNA splicing. Alternatively spliced transcript variants have been described. Related pseudogenes exist on chromosomes 9 and 15. [provided by RefSeq, Mar 2009]
- ENST00000379888
- ENSP00000369218
- ENSG00000134453
- ENST00000446108
- ENSP00000388638
- SPF45
- SPF45
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
interacting protein | 0.96 | ||
virus perturbation | 0.94 | ||
transcription factor binding site profile | 0.85 | ||
ligand (protein) perturbation | 0.83 | ||
transcription factor perturbation | 0.74 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 25.76 (req: < 5)
Gene RIFs: 17 (req: <= 3)
Antibodies: 102 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 25.76 (req: >= 5)
Gene RIFs: 17 (req: > 3)
Antibodies: 102 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 5
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 5
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0